Condition: Schizophrenia · Sponsor: Bristol-Myers Squibb
A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Collaborative Neuroscience Research, LLC | Los Alamitos, California, United States | Recruiting |
| Research Centers of America ( Hollywood ) | Hollywood, Florida, United States | Recruiting |
| Innovative Clinical Research, Inc. | Miami Lakes, Florida, United States | Recruiting |
| Atlanta Center for Medical Research | Atlanta, Georgia, United States | Recruiting |
| CenExel iResearch, LLC | Decatur, Georgia, United States | Recruiting |
| Uptown Research Institute | Chicago, Illinois, United States | Recruiting |
| Hassman Research Institute Marlton Site | Marlton, New Jersey, United States | Recruiting |
| Community Clinical Research | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07061288